SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Manolagas SC 2000 Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21: 115137.
  • 2
    Weinstein RS, Manolagas SC 2000 Apoptosis and osteoporosis. Am J Med 108: 153164.
  • 3
    Aubin JE, Bonnelye E 2000 Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int 11: 905913.
  • 4
    Oyajobi BO, Anderson DM, Traianedes K, Williams PJ, Yoneda T, Mundy GR 2001 Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res 61: 25722578.
  • 5
    Tsuda E 2002 Osteoclastogenesis inhibitory factor (OCIF)/OPG (a novel therapeutic candidate for the treatment of metabolic bone diseases). Nippon Rinsho 60 (Suppl 3): 679687.
  • 6
    Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L 1997 A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390: 175179.
  • 7
    Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95: 35973602.
  • 8
    Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM 1999 OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397: 315323.
  • 9
    Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165176.
  • 10
    Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, Rattan A, Scully S, Fletcher F, Juan T, Kelley M, Burgess TL, Boyle WJ, Polverino AJ 2000 Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 157: 435448.
  • 11
    Jimi E, Akiyama S, Tsurukai T, Okahashi N, Kobayashi K, Udagawa N, Nishihara T, Takahashi N, Suda T 1999 Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol 163: 434442.
  • 12
    Fuller K, Wong B, Fox S, Choi Y, Chambers TJ 1998 TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 188: 9971001.
  • 13
    Wong BR, Besser D, Kim N, Arron JR, Vologodskaia M, Hanafusa H, Choi Y 1999 TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell 4: 10411049.
  • 14
    Glantschnig H, Fisher JE, Wesolowski G, Rodan GA, Reszka AA 2003 M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ 10: 11651177.
  • 15
    Lee SJ, Zhou T, Choi C, Wang Z, Benveniste EN 2000 Differential regulation and function of Fas expression on glial cells. J Immunol 164: 12771285.
  • 16
    Kitaura H, Nagata N, Fujimura Y, Hotokezaka H, Yoshida N, Nakayama K 2002 Effect of IL-12 on TNF-alpha-mediated osteoclast formation in bone marrow cells: Apoptosis mediated by Fas/Fas ligand interaction. J Immunol 169: 47324738.
  • 17
    Wu X, McKenna MA, Feng X, Nagy TR, McDonald JM 2003 Osteoclast apoptosis: The role of Fas in vivo and in vitro. Endocrinology 144: 55455555.
  • 18
    Ahn EY, Pan G, Vickers SM, McDonald JM 2002 IFN-gamma upregulates apoptosis-related molecules and enhances Fas-mediated apoptosis in human cholangiocarcinoma. Int J Cancer 100: 445451.
  • 19
    Dybedal I, Yang L, Bryder D, Aastrand-Grundstrom I, Leandersson K, Jacobsen SE 2003 Human reconstituting hematopoietic stem cells up-regulate Fas expression upon active cell cycling but remain resistant to Fas-induced suppression. Blood 102: 118126.
  • 20
    Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL 2003 Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 111: 12211230.
  • 21
    McHugh KP, Hodivala-Dilke K, Zheng MH, Namba N, Lam J, Novack D, Feng X, Ross FP, Hynes RO, Teitelbaum SL 2000 Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 105: 433440.
  • 22
    Kameda T, Ishikawa H, Tsutsui T 1995 Detection and characterization of apoptosis in osteoclasts in vitro. Biochem Biophys Res Commun 207: 753760.
  • 23
    Zayzafoon M, Abdulkadir SA, McDonald JM 2004 Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines. J Biol Chem 279: 36623670.
  • 24
    Zheng Y, Ouaaz F, Bruzzo P, Singh V, Gerondakis S, Beg AA 2001 NF-kappa B RelA (p65) is essential for TNF-alpha-induced fas expression but dispensable for both TCR-induced expression and activation-induced cell death. J Immunol 166: 49494957.
  • 25
    Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, Miyata T, Anderson DM, Suda T 1999 Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappa B (RANK) receptors. J Exp Med 190: 17411754.
  • 26
    Wei S, Teitelbaum SL, Wang MW, Ross FP 2001 Receptor activator of nuclear factor-kappa b ligand activates nuclear factor-kappa b in osteoclast precursors. Endocrinology 142: 12901295.
  • 27
    Prestwood KM, Pilbeam CC, Burleson JA, Woodiel FN, Delmas PD, Deftos LJ, Raisz LG 1994 The short-term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab 79: 366371.
  • 28
    Naoyuki Takahashi NU Takami M, Suda T 2002 Principles of bone biology (cells of bone). In: BilezikianJP, RaiszLG, RodanGA (eds.) Principles of Bone Biology, 2nd ed., vol. 1. Academic Press, San Diego, CA, USA, pp. 109123.
  • 29
    Bharti AC, Takada Y, Shishodia S, Aggarwal BB 2004 Evidence that receptor activator of nuclear factor (NF)-kappaB ligand can suppress cell proliferation and induce apoptosis through activation of a NF-kappaB-independent and TRAF6-dependent mechanism. J Biol Chem 279: 60656076.
  • 30
    Wang XM, Yu SF, Yang ZP 2000 Apoptosis of osteoclast-like cells induced by alendronate is related to Fas gene expression. Chin J Dent Res 3: 2632.
  • 31
    Sun YM, Yang FJ, Li YM, Lu B, Zhu M, Qiu MC 2002 Expression of Fas, FasL, and NF-kappa B in the process of osteoclast-like cell apoptosis effected by sodium fluoride. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 24: 491494.
  • 32
    Brazil JJ, Gupta P 2002 Constitutive expression of the fas receptor and its ligand in adult human bone marrow: A regulatory feedback loop for the homeostatic control of hematopoiesis. Blood Cells Mol Dis 29: 94103.
  • 33
    Hatakeyama S, Tomichi N, Ohara-Nemoto Y, Satoh M 2000 The immunohistochemical localization of Fas and Fas ligand in jaw bone and tooth germ of human fetuses. Calcif Tissue Int 66: 330337.
  • 34
    Ozeki N, Mogi M, Nakamura H, Togari A 2002 Differential expression of the Fas-Fas ligand system on cytokine-induced apoptotic cell death in mouse osteoblastic cells. Arch Oral Biol 47: 511517.
  • 35
    Stahnke K, Hecker S, Kohne E, Debatin KM 1998 CD95 (APO-1/FAS)-mediated apoptosis in cytokine-activated hematopoietic cells. Exp Hematol 26: 844850.
  • 36
    Maciejewski J, Selleri C, Anderson S, Young NS 1995 Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 85: 31833190.
  • 37
    Woo KM, Kim HM, Ko JS 2002 Macrophage colony-stimulating factor promotes the survival of osteoclast precursors by up-regulating Bcl-X(L). Exp Mol Med 34: 340346.
  • 38
    Biancone L, Martino AD, Orlandi V, Conaldi PG, Toniolo A, Camussi G 1997 Development of inflammatory angiogenesis by local stimulation of Fas in vivo. J Exp Med 186: 147152.
  • 39
    Shinohara H, Yagita H, Ikawa Y, Oyaizu N 2000 Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase activation. Cancer Res 60: 17661772.
  • 40
    Wong BR, Josien R, Lee SY, Sauter B, Li HL, Steinman RM, Choi Y 1997 TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 186: 20752080.
  • 41
    Kuhnel F, Zender L, Paul Y, Tietze MK, Trautwein C, Manns M, Kubicka S 2000 NFkappaB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis. J Biol Chem 275: 64216427.